Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy

NCT02223819 is registered in ClinicalTrials.gov with Columbia University as lead sponsor.

NCT NCT02223819
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02223819 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Lead sponsor
Columbia University
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2015
Completion date
July 3, 2019
Enrollment
34 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

uveal melanoma